Evidence map›Paper›PMID 34203777›Full record

ArticleMembranes2021

Aminophosphonates in Nanofiltration and Reverse Osmosis Permeates.

Ramona Kuhn, Carsten Vornholt, Volker Preuß, Isaac Mbir Bryant, Marion Martienssen

Abstract read
In one paragraph

Article in Membranes, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Ramona KuhnChair of Biotechnology of Water Treatment, Brandenburg University of Technology Cottbus/Senftenberg, 03046 Cottbus, Germany.
Carsten VornholtChair of Water Treatment and Urban Hydraulic Engineering, Brandenburg University of Technology Cottbus/Senftenberg, 03046 Cottbus, Germany.
Volker PreußChair of Water Treatment and Urban Hydraulic Engineering, Brandenburg University of Technology Cottbus/Senftenberg, 03046 Cottbus, Germany.
Isaac Mbir BryantDepartment of Environmental Science, University of Cape Coast, Cape Coast 4P4872, Ghana.
Marion MartienssenChair of Biotechnology of Water Treatment, Brandenburg University of Technology Cottbus/Senftenberg, 03046 Cottbus, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aminophosphonates such as aminotris(methylenephosphonic acid) (ATMP) are common constituents of antiscalants. In nanofiltration (NF) and reverse osmosis (RO) processes, ATMP prevents inorganic scaling leading to more stable membrane performance. So far, little attention has been paid to the possible permeation of aminophosphonates through NF and RO membranes. We have investigated the permeability of these membrane types for ATMP and its potential metabolites iminodi(methylenephosphonic acid) (IDMP) and amino(methylenephosphonic acid) (AMPA) with two different NF membranes (TS40 and TS80) and one RO membrane (ACM2) and three different water compositions (ultra-pure water, synthetic tap water and local tap water). We found traces of phosphonates in all investigated permeates. The highest phosphonate rejection occurred with local tap water for all three membranes investigated. Filtration experiments with a technical antiscalant formulation containing ATMP indicated similar trends of phosphonate permeability through all three membranes. We assume that the separation mechanisms of the membranes are the results of a very complex relationship between physico-chemical properties such as Donnan exclusion, feed pH, feed ionic strength and feed concentration, as well as solute-solute interactions.

Indexed as

AMPAantiscalantsATMPdrinking water treatmentnanofiltrationphosphonatesreverse osmosis

Identifiers

PMID34203777
PMCPMC8232610

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.